Sanofi scores with its subcutaneous version of Sarclisa as it tries to play catch up with J&J's Darzalex

9th January 2025 Uncategorised 0

With an on-body delivery system (OBDS) to deliver its subcutaneous (SC) formulation of Sarclisa, Sanofi may be finding the edge it needs to compete with Johnson & Johnson’s Darzalex in multiple myeloma. Sanofi has taken a major step in the development of its OBDS as a phase 3 trial has met its primary co-endpoints, showing non-inferiority to intravenous (IV) Sarclisa, the company said.

More: Sanofi scores with its subcutaneous version of Sarclisa as it tries to play catch up with J&J's Darzalex
Source: fierce